M.D. Anderson Cancer Center: Triple Negative Breast Neoplasms trials

The registry lists 22 Triple Negative Breast Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 4 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 5Phase 2 13No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER TrialNot yet recruitingNCT07610525Phase 2
• Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingNCT07011654Phase 1/2
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerRecruitingNCT06318897Phase 2
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyRecruitingNCT02945579Not applicable
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedNCT04789668Phase 1/2Results posted
• Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedNCT04216472Phase 2Results posted
• Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyTerminatedNCT03872388Phase 2Results posted
• Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerCompletedNCT03106077Phase 2Results posted
• Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerCompletedNCT02689427Phase 2Results posted
• Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCCompletedNCT02593175Phase 2Results posted
• Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerCompletedNCT02530489Phase 2Results posted
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results posted
• Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast CancerCompletedNCT05071677
• M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerTerminatedNCT03579472Phase 1
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
• Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)SuspendedNCT02993068Not applicable
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerActive, not recruitingNCT02876107Phase 2
• DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast CancerActive, not recruitingNCT02744053Early Phase 1
• Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of SurgeryActive, not recruitingNCT02455791Not applicable
• Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeActive, not recruitingNCT02276443Not applicable
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
• Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)WithdrawnNCT01333423Phase 1